Zerbor/iStock via Getty Images
Danaher Corporation (NYSE:DHR) traded ~1% lower in the premarket on Tuesday as investors reacted to the life sciences company’s better-than-expected Q1 2025 financials and its full-year earnings outlook, which stood in line with consensus on an adjusted basis.
The Washington, DC-based